ArticleAlcoholism, clinical and experimental research2019
Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis.
Article in Alcoholism, clinical and experimental research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05375682 (Integrating Care for Patients With Alcohol Liver Disease and Mental Health and Alcohol Use Disorders), which is not on this map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrating Care for Patients With Alcohol Liver Disease and Mental Health and Alcohol Use Disorders: A Pilot Study
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- Pharmacological therapies for alcohol use disorder reduce hepatic decompensation & mortality in alcohol-related liver disease: A GRADE evaluation through a meta-analysis.The Indian journal of medical research · 2025Pooled it
- Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis.Journal of addiction medicinePooled it
- Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol-related liver disease: Findings from a pilot randomized controlled trial.Alcohol, clinical & experimental research · 2025Trial
- Sexual dimorphism in the liver.Nature reviews. Gastroenterology & hepatology · 2026Review
- Psychosocial Risk Factors and Outcomes Among Men and Women With Alcohol-Associated Liver Disease Undergoing Transplant Evaluation.Alcohol, clinical & experimental research · 2026Article
- Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.JMIR research protocols · 2026Article
- Provider attitudes, practices, and barriers in alcohol-associated liver disease care: Findings from the CASL ALD SIG national survey.Canadian liver journal · 2026Article
- Letter to the editor on "Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States".Clinical and molecular hepatology · 2026Article
- Reply to correspondence 2 on "Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States".Clinical and molecular hepatology · 2026Article
- Gender disparities in liver transplantation.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Medications for Alcohol Use Disorder Among Patients With Severe Alcohol-Related Liver Disease.JAMA network open · 2026Article
- Rising burden of alcohol-associated liver disease and cancers: Insights into sex disparities and policy implications: Editorial on "Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States".Clinical and molecular hepatology · 2026Article
- Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis.BMJ public health · 2026Article
- Reply to correspondence 1 on "Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States".Clinical and molecular hepatology · 2026Article
- Reducing alcohol-associated liver disease burden in the general population.The lancet. Gastroenterology & hepatology · 2025Review
- Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.Current gastroenterology reports · 2025Review
- Hepatology clinician readiness to provide addiction treatment in hepatology clinics: A mixed-methods formative evaluation.Hepatology communications · 2025Article
- "The alcohol-harm paradox": Understanding socioeconomic inequalities in liver disease.JHEP reports : innovation in hepatology · 2025Review
- Sex differences in severity, outcomes, and healthcare utilization in alcohol-associated hepatitis.World journal of hepatology · 2025Article
- Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States.Clinical and molecular hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe burden of alcohol-associated cirrhosis (AC) is high, and though alcohol cessation improves mortality, many patients fail to engage in alcohol use disorder (AUD) treatment and continue drinking. Our aim was to determine rates, predictors, and outcomes of AUD treatment utilization in AC patients with private insurance.
methodsWe collected data from persons with AC (diagnosed by ICD-9/ICD-10 codes), aged 18 to 64 years, enrolled in the Truven MarketScan Commercial Claims and Encounters database (2009 to 2016). We determined rates and predictors of substance abuse treatment visits as well as rates of alcohol relapse prevention medication prescriptions, weighted to the national employer-sponsored insured population. Effects of AUD treatment utilization on decompensation rates were calculated using proportional hazards regression with propensity score adjustment.
resultsA total of 66,053 AC patients were identified, 32% were female, and mean age at diagnosis was 54.5 years. About 72% had insurance coverage for substance abuse treatment. Overall, AUD treatment utilization rates were low, with only 10% receiving a face-to-face mental health or substance abuse visit and only 0.8% receiving a Food and Drug Administration (FDA)-approved relapse prevention medication within 1 year of index diagnosis. Women were less likely to receive a face-to-face visit (hazard ratio [HR] 0.84, p < 0.001) or an FDA-approved relapse prevention medication (0.89, p = 0.05) than men. AC patients who had a clinic visit for AUD treatment or used FDA-approved relapse medication showed decreased risk of decompensation at 1 year (HR 0.85, p < 0.001 for either).
conclusionsAUD treatment utilization is associated with lower decompensation rates among privately insured patients with AC. Women were less likely to utilize AUD treatment visits. Efforts to reduce gender-specific barriers to treatment are urgently needed to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.